Hypertension, Pulmonary Clinical Trial
Official title:
Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension
This study aims to investigate the exercise profile in pulmonary hypertension patients with either pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension or pulmonary hypertension due to left heart disease and in disease control.
This is a dual-center observational prospective study in patients with pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension due to left heart disease. Patients undergoing right heart catheterisation due to dyspnoe with invasive exclusion of pulmonary hypertension will be recruited as disease control. The study comprises a 1-day screening period, followed by a right heart catheterization with exercise challenge. The study starts with screening, information of the patients and Informed Consent Form signature at day -1. Screening and inclusion of the patient can be performed on the same day. On the day of the planned right heart catheterization based on clinical grounds, exercise right heart catheterisation (RHC) using Swan-Ganz and/or Conductance catheters with simultaneous echocardiography will be performed. End of study is defined as a complete exercise RHC. Adverse events will be assessed until 1 day after the exercise RHC. After placement of the Swan-ganz or Conductance catheter patients will undergo an exercise challenge using the following protocol in semi-supine position until exhaustion: - Incremental workload increase of 20Watt every 2-4 min. - For patients not able to start a 20 Watt, initial workload can be adjusted to a minimum of 5 Watt with 5 Watt increase every 2-4 min until exhaustion - Maximal exercise duration is 10-12 minutes - Symptoms of dyspnoea during exercise will be rated by subjects at baseline, after 6 minutes and at maximum according to the Borg perceived dyspnoea (0-10) scale. Simultaneously, echocardiography and lung ultrasound will be performed before exercise (baseline), after 6 minutes of exercise and at maximum. After assessment of right ventriclure pressure-volume loops during maximum exercise, guided by echocardiographic the conductance catheter will be placed in the right atrium to obtain right atrium pressure-volume loops during maximum exercise. Optional, the exercise RHC will be performed without the Conductance catheter and only with the Swan-Ganz catheter. In this case, pressure values and cardiac output will be measured using the thermodilution method, averaging 3-5 measurements at baseline, 6 minutes and maximum. Detailed assessment of right atrial pressure curves (with a and v wave) will be performed at baseline, 6 minutes and maximum exercise. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
| Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
| Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
| Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
| Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
| Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
| Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
| Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
| Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
| Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
| Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
| Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
| Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
| Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
| Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
| Completed |
NCT01317134 -
Endothelial Function in Patients With Pulmonary Arterial Hypertension
|
N/A |